Clinical evaluation of phenserine tartrate extended controlled release tablet (ECRT) formulation in early mild alzheimer's disease and mild to moderate traumatic brain injury.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95024D00002
- Awardee
-
University Of Exeter UEI ZNQ1VJLJQ827
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 2 $1,366,275 obligated
Award facts
- Opportunity
-
- Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer’s disease and mild to moderate traumatic brain injury Pre-Solicitation · 75N95022R00041 · Posted Mar 15, 2022
- Combined order value
- $1,366,275 Current and potential, with all options
- Last date to order 79% complete
- IDV ceiling 69% used
- $1,988,692.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Funding agency
- National Institute on Aging National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute on Aging awarded a single-award indefinite delivery contract to University Of Exeter valued at $1,988,692 on February 1, 2024, to conduct clinical evaluation of phenserine tartrate extended-controlled release tablet (ECRT) formulation in early mild Alzheimer's disease and mild to moderate traumatic brain injury.
Place of performance is Great Britain, United Kingdom. The IDIQ has a period of performance through August 1, 2027. Under this vehicle, the University of Exeter is tasked to conduct clinical trials, perform brain imaging and cognitive assessments, and analyze biomarkers to evaluate the pharmacology of the investigational treatment.
A delivery order issued February 1, 2024, valued at $962,486 with a cost-no-fee pricing structure, carries a completion date of January 31, 2026, and constitutes the primary task order activity under this IDIQ to date. This order funds the same clinical evaluation scope for early mild Alzheimer's disease and mild to moderate traumatic brain injury populations.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95024D00002?
75N95024D00002 was awarded to University Of Exeter by National Institute on Drug Abuse (National Institutes of Health) on February 1, 2024.
How much is contract 75N95024D00002 worth?
Orders under 75N95024D00002 have obligated $1,366,275. 75N95024D00002's own ceiling is $1,988,692.
How many orders have been placed under contract 75N95024D00002?
2 orders have been placed under 75N95024D00002, the latest on February 1, 2024.
Which agency awarded contract 75N95024D00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024D00002, with funding from National Institute on Aging (National Institutes of Health).
Who can order from contract 75N95024D00002?
75N95024D00002 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95024D00002 competed?
The extent of competition for 75N95024D00002 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV